Avrobio Inc traded at $0.90 this Monday January 30th, increasing $0.01 or 1.24 percent since the previous trading session. Looking back, over the last four weeks, Avrobio Inc gained 18.05 percent. Over the last 12 months, its price fell by 53.61 percent. Looking ahead, we forecast Avrobio Inc to be priced at 0.86 by the end of this quarter and at 0.78 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 4,090.00 -45.00 -1.09% 23.75%
Akebia Therapeutics 0.60 -0.07 -9.85% -69.65%
Alnylam Pharmaceuticals 225.40 -5.97 -2.58% 63.81%
Bluebird Bio 6.11 -0.17 -2.71% -22.56%
Gilead Sciences 83.77 0.42 0.50% 22.35%
Intercept Pharmaceuticals 17.94 -0.46 -2.50% 9.46%
Ionis Pharmaceuticals 39.24 -0.78 -1.95% 23.40%
Karyopharm Therapeutics 3.08 -0.10 -3.14% -65.39%
MacroGenics 5.62 -0.12 -2.09% -54.49%
Pfizer 43.87 0.32 0.73% -17.34%
Roche Holding 284.55 -3.65 -1.27% -20.86%
Sanofi 89.89 0.10 0.11% -1.86%
Sangamo BioSciences 3.40 -0.18 -5.03% -43.62%
Sarepta Therapeutics 120.86 -2.03 -1.65% 68.87%


Avrobio Inc
AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.